Results 141 to 150 of about 34,322 (240)

Evaluation of a Therapeutic Drug Monitoring Strategy for Adalimumab in Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study. [PDF]

Clin Transl Sci
Pan S, Tsakok T, Wei R, Dand N, Loeff FC, Bloem K, de Vries A, Baudry D, Duckworth M, Pushpa-Rajah A, Russell A, Alsharqi A, Becher G, Murphy R, Wahie S, Wright A, Griffiths CEM, Reynolds NJ, Barker J, Warren RB, Burden AD, Rispens T, Mahil SK, Standing JF, Smith CH, BADBIR Study Group, BSTOP Study Group and the PSORT Consortium.   +26 more
europepmc   +1 more source

Genomic and proteomic insights into hidradenitis suppurativa

Journal of the European Academy of Dermatology and Venereology, EarlyView.
A dual pathogenic model of HS involving both epithelial dysfunction and systemic inflammation is supported. The HLA‐DRA association hints at autoimmune overlap, but the proteomic signature which is dominated by innate immune mediators favours an autoinflammatory classification, which may guide future therapeutic strategies and patient stratification ...
Maria Argyropoulou, Emmanouil Stylianakis, Isis Ricaño‐Ponce, Nick Keur, Theodora Kanni, Dimitra Stergianou, Mihai G. Netea, Vinod Kumar, Evangelos J. Giamarellos‐Bourboulis   +8 more
wiley   +1 more source

A Comparative Study of Different Biological Drugs in First-Line Therapy in Crohn's Disease: A Multicenter Descriptive Analysis. [PDF]

Medicina (Kaunas)
Gila A, Preda CM, Diculescu M, Bratu RM, Istratescu D, Stroie T, Trifan A, Tantau A, Bucurica S, Tieranu CG, Minea H, Buzuleac AM, Negreanu L, Popescu R, Ciora CA.   +14 more
europepmc   +1 more source

International consensus on dose reduction of biologics for patients with psoriasis: The DR. Delphi study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Dermatologists worldwide reached consensus on criteria for dose reduction (DR) of biologics for psoriasis resulting in a DR algorithm for adalimumab, etanercept and ustekinumab. DR of IL‐17 and IL‐23 inhibitors was deemed feasible as well. This first international consensus provides essential information for uptake of biologic DR for psoriasis globally.
C. A. M. van Riel, W.‐H. Boehncke, J. L. W. Lambert, P. I. Spuls, L. S. van der Schoot, I. van Ee, E. M. G. J. de Jong, J. M. P. A. van den Reek, on behalf of the eDelphi consortium, M. Elkalioby, L. Fianen, L. Linhares Leite, C. Boesjes, S. Mahil, M. Franco, F. Valenzuela, C. Chaiyabutr, M. A. Lorna, F. Frez, O. Zargari, T. Hillary, H. Oon, L. Skov, M. Gupta, E. Sotiriou, N. Nguyen Loft, R. Ceovic, K. M. G. Klaassen, J. Wikström, C. Zachariae, P. Asawanonda, R. Vender, A. Carvalho, J. Song, C. Lan, J.‐T. Maul, D. Jullien, B. Hidalgo‐Matlock, A. Duvetorp, M. Gkini, D. Ioannidis, W. Veldkamp, J. Hugo, J. Barboza, A. Carugno, A. Londoño‐García, L. Schneller‐Pavelescu Apetrei, M. Ferran, F. Lafuente Urrez, N. Merino, M. Llamas Velasco, L. Puig, M. Bourcier, M. Perez Ferriols, T. Leonidze, D. Armijo, A. Eylenbosch, M. B. A. van Doorn, P. P. M. van Lumig, P. Ghislain, A. Nast, S. Lanssens, E. Sonkoly, D. J. Hijnen, E. M. Baerveldt, P. Gisondi, M. Tjioe, I. Haeck, K. Agerberg, Y. Okubo   +69 more
wiley   +1 more source

Kangfuxin liquid enema plus adalimumab for ulcerative colitis: a retrospective cohort study. [PDF]

Am J Transl Res
Zhao M, Yu T.
europepmc   +1 more source

Treatment‐associated phenotype switching between psoriasis and atopic dermatitis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This international, multicentre real‐world study of 148 patients’ documents treatment‐associated, bidirectional phenotype switching between psoriasis and atopic dermatitis. Psoriasis‐to‐eczematous switches occurred predominantly with IL‐17 and IL‐23 inhibitors, whereas AD‐to‐psoriasiform switches occurred exclusively during treatment with biologic ...
Tiago Torres, Mario Valenti, Anna Balato, Matteo Megna, Paolo Gisondi, Vimal Prajapati, Stefano Piaserico, Julia‐Tatjana Maul, Lara Valeska Maul, Jose Manuel Carrascosa, Francisco José Navarro‐Triviño, Elizabeth Lazaridou, César Ferreira, Jacopo Tartaglia, Christian Ciolfi, Athina‐Ioanna Daponte, Eugenia Veronica Di Brizzi, Maddalena Napolitano, Barbara Leal Guerra, Monica Munera‐Campos, Siddhartha Sood, Silvia Ferruci, Francesca Prignano, Esteban Dauden, Mar Llamas‐Velasco, Ron Vender, Jensen Yeung, Angelo Marzano, Luis Puig   +28 more
wiley   +1 more source

Evaluating Antibody Quality via Simultaneous Size and Charge Measurement with Single Protein Oscillators. [PDF]

Anal Chem
Jia R, Porter RM, Dangi RS, Graham J, Bora K, Kaligotla H, Kwan S, Zhou X, Jiang J, Xu Y, Chieng A, Wan Z, Wang S.   +12 more
europepmc   +1 more source

Proteomic analysis in hidradenitis suppurativa reveals systemic inflammation in all disease stages

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Proteomic profiling reveals systemic inflammation in patients with hidradenitis suppurativa, even in early disease. Distinct mediators (e.g. TGF‐α, OSM, HGF) are elevated early, whereas others correlate with clinical severity (e.g. IL‐6, VEGF‐A, IL‐17A) or disease duration (e.g.
Lotta Sandelin Francke, Ansam Al‐Bayatti, Hanqian Zhang, Mohammad Alimohammadi, Hans Törmä, Enikö Sonkoly   +5 more
wiley   +1 more source

Comparative Study Assessing Multiple Switches Between Biosimilar ABP 501 (adalimumab-atto) and Adalimumab Reference Product in Patients with Plaque Psoriasis. [PDF]

Adv Ther
Yamauchi PS, Chow V, Mytych DT, Zhou M, Radziszewski W.   +4 more
europepmc   +1 more source

Measuring success in HS treatment from the physician's and the patient's perspective

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Integrated clinician (HiSCR, IHS4, IHS4‐55, HS‐IGA) and patient (HiSQOL, DLQI) scores, combined with imaging‐based fibrosis and inflammation assessment, redefine treatment success in hidradenitis suppurativa by aligning treat‐to‐target strategies with both inflammatory control and irreversible structural damage.
Georgios Nikolakis, Monika Arenbergerova, Zeljko Mijuskovic, Baoxi Wang, Christos C. Zouboulis   +4 more
wiley   +1 more source